Austrade’s Success Stories article highlights our focus in tackling the growing threat of antimicrobial resistance using precision medicine. SpeeDx develops clinical diagnostic tests which are faster and more accurate in detecting diseases that have high level of drug resistance. Our first test targets a sexually transmitted infection (STI) known as Mycoplasma genitalium, which has about 40% resistance rate in Australia. It can identify the STI within 24 hours and provide information on the antibiotic resistance status of the organism. Using this test, healthcare providers can customise patient treatment according to the resistance status – potentially replacing the empirical model currently used to treat this infection. The article also outlines SpeeDx’ next product pipelines, plans for international expansion and recent collaborations to expand the applications of our technology to other industries.
The full article can be found here: Australian medical diagnostic technology company in the global fight against drug resistance